Study of PD-1 Expression in T Cells Across Various Solid Tumors Including Head and Neck, Ovarian, Cervical, and Lung Cancer

What this Trial Is About

Researchers are studying the expression of PD-1 on T cells in patients with various local or metastatic solid tumors, including head and neck, ovarian, cervical, pre-invasive cervical cancer, glioblastoma, non-small cell lung cancer, and anal cancer. This prospective cohort study involves 1100 patients and aims to better understand immune mechanisms in these cancers. Each tumor type is treated as a separate group for analysis. Participants will receive standard anticancer treatments as part of their usual care. Biological samples including tumor tissue, blood, and ascites if applicable will be collected at multiple time points, such as baseline, during surgeries or biopsies, every six months, and at disease progression or recurrence. For those receiving radiotherapy, blood samples will be taken before, at the end, and three months after treatment. The study will follow each patient for up to five years. During the study, patients will undergo sample collections aligned with their clinical care schedule. Researchers will measure the percentage of CD4 and CD8 T cells expressing PD-1 over five years, as well as the presence of tissue resident memory T cells in tumor samples. Participation involves regular monitoring through blood tests and biopsies when clinically indicated, with continued follow-up to observe immune changes related to cancer progression and treatment.

Deciphering Mechanisms Underlying Cancer Immunogenicity